Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
EGR2 is an epigenomic regulator of phagocytosis and antifungal immunity in alveolar macrophages
Zsuzsanna Kolostyak, Dora Bojcsuk, Viktoria Baksa, Zsuzsa Mathene Szigeti, Krisztian Bene, Zsolt Czimmerer, Pal Boto, Lina Fadel, Szilard Poliska, Laszlo Halasz, Petros Tzerpos, Wilhelm K. Berger, Andres Villabona-Rueda, Zsofia Varga, Tunde Kovacs, Andreas Patsalos, Attila Pap, Gyorgy Vamosi, Peter Bai, Balazs Dezso, Matthew Spite, Franco R. D’Alessio, Istvan Szatmari, Laszlo Nagy
Zsuzsanna Kolostyak, Dora Bojcsuk, Viktoria Baksa, Zsuzsa Mathene Szigeti, Krisztian Bene, Zsolt Czimmerer, Pal Boto, Lina Fadel, Szilard Poliska, Laszlo Halasz, Petros Tzerpos, Wilhelm K. Berger, Andres Villabona-Rueda, Zsofia Varga, Tunde Kovacs, Andreas Patsalos, Attila Pap, Gyorgy Vamosi, Peter Bai, Balazs Dezso, Matthew Spite, Franco R. D’Alessio, Istvan Szatmari, Laszlo Nagy
View: Text | PDF
Research Article Infectious disease Inflammation

EGR2 is an epigenomic regulator of phagocytosis and antifungal immunity in alveolar macrophages

  • Text
  • PDF
Abstract

Alveolar macrophages (AMs) act as gatekeepers of the lung’s immune responses, serving essential roles in recognizing and eliminating pathogens. The transcription factor (TF) early growth response 2 (EGR2) has been recently described as required for mature AMs in mice; however, its mechanisms of action have not been explored. Here, we identified EGR2 as an epigenomic regulator and likely direct proximal transcriptional activator in AMs using epigenomic approaches (RNA sequencing, ATAC sequencing, and CUT&RUN). The predicted direct proximal targets of EGR2 included a subset of AM identity genes and ones related to pathogen recognition, phagosome maturation, and adhesion, such as Clec7a, Atp6v0d2, Itgb2, Rhoc, and Tmsb10. We provided evidence that EGR2 deficiency led to impaired zymosan internalization and reduced the capacity to respond to Aspergillus fumigatus. Mechanistically, the lack of EGR2 altered the transcriptional response, secreted cytokines (i.e., CXCL11), and inflammation-resolving lipid mediators (i.e., RvE1) of AMs during in vivo zymosan-induced inflammation, which manifested in impaired resolution. Our findings demonstrated that EGR2 is a key proximal transcriptional activator and epigenomic bookmark in AMs responsible for select, distinct components of cell identity and a protective transcriptional and epigenomic program against fungi.

Authors

Zsuzsanna Kolostyak, Dora Bojcsuk, Viktoria Baksa, Zsuzsa Mathene Szigeti, Krisztian Bene, Zsolt Czimmerer, Pal Boto, Lina Fadel, Szilard Poliska, Laszlo Halasz, Petros Tzerpos, Wilhelm K. Berger, Andres Villabona-Rueda, Zsofia Varga, Tunde Kovacs, Andreas Patsalos, Attila Pap, Gyorgy Vamosi, Peter Bai, Balazs Dezso, Matthew Spite, Franco R. D’Alessio, Istvan Szatmari, Laszlo Nagy

×

Figure 3

EGR2 affects gene expression and epigenomic features of AMs and embryonic stem cell–derived progenitors.

Options: View larger image (or click on image) Download as PowerPoint
EGR2 affects gene expression and epigenomic features of AMs and embryoni...
(A) The box plots show the coverage (decile normalized average RPKM) of the H3K4me3 mark at the TSSs, BRD4 mark at EGR motif–containing coupled enhancers of absolutely and relatively EGR2-dependent repressed genes, repressed genes associated with closing DARs without EGR motif, and induced genes associated with opening DARs. (B) Integrative Genomic Viewer (IGV) snapshots represent the H3K4me3 mark at the indicated genes’ promoters and BRD4 signal at the coupled EGR motif–containing enhancers. (C) The box plots show the coverage (decile normalized average RPKM) values calculated from BRD4 CUT&RUN on the peak 200 bp regions of the EGR2-dependent peaks. (D) IGV visualization of RNA-Seq and ATAC-Seq coverages (overlaid) and the EGR motif on Kazald1. (E) The columns represent the relative eRNA expression (mean ± SEM) of Kazald1-related closing DARs with EGR motif in Egr2+/+ (n = 4) and Egr2fl/fl (n = 5) samples. (F) The scheme of the gain-of-function experimental procedure applying ESC differentiation model toward myeloid progenitors. (G) The bar diagrams represent the relative mRNA expression (mean ± SEM) values of Egr2 and AM marker Cd11c and SiglecF genes in untreated (-dox) or doxycycline-treated (+dox) myeloid progenitors (n = 4). (H) The box plots show the CD11c and SIGLECF proteins’ (median fluorescence intensity [MFI] ± SEM) in untreated (-dox) or doxycycline-treated (+dox) myeloid progenitors determined by flow cytometry (n = 4). (I and J) Column diagram representations of the relative mRNA (I) and eRNA (J) expression (mean ± SEM) values of representative EGR2-dependent genes (I) and the associated enhancers (J) in untreated (-dox) or doxycycline-treated (+dox) myeloid progenitors (n = 4) (t test, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts